Clinical trials of conjunctive anticoagulant strategies in thrombolysis

Coronary Artery Disease

Volumn 7, Issue 7, 1996, Pages 508-515

  Kleiman, Neal S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

platelets; thrombin; thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; EFEGATRAN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; HIRULOG; RIDOGREL; STREPTOKINASE; THROMBIN; THROMBIN INHIBITOR; THROMBOXANE A2; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE HEART INFARCTION; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION;

EID: 0029907136     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199607000-00004     Document Type: Review

References (100)

1. Chesebro J, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al.: Thrombolysis in myocardial infarction (TIMI) Trial. Phase I: a comparision between intravenous plasminogen activator and intravenous streptokinase. Circulation 1987, 76:142-154.
2. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993, 329:723-725.
3. The GUSTO Angiographic Investigators: The effects of tissue plasminogen activator or streptokinase or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993, 329:1650-1652. This study established the relationship between antegrade coronary arterial flow and survival.
4. Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, et al.: Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993, 270:1211-1216.
5. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al.: A comparision of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993, 328:673.
6. Meijer A, Verheugt FW, Werter CJ, Lie KI, van der Pol JM, van Eenige MJ: Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT study. Circulation 1993, 87:1524-1530.
7. Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, et al.: Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation 1991, 82:781-791. This study demonstrates the outcomes in patients who develop reocclusion.
8. Meyer BJ, Badimon JJ, Mailhac A, Fernandez-Ortiz A, Chesebro JH, Fuster V, et al.: Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy. Circulation 1994, 90:2432-2438.
9. Blomback B, Blomback M, Hessel B, Iwanaga S: Structure of N-terminal fragments of fibrinogen and specificity of thrombin. Nature 1967, 215:1445-1448.
10. Davey MG, Luscher EF: Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature 1967, 216:857-858.
11. Vu T, Hung D, Wheaton V, Coughlin S: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991, 64:1057-1068.
12. Tans G, Nicolaes GA, Thomassen MC, Hemker HC, van Zonneveld AJ, Pannekoek H, et al.: Activation of human factor V by meizothrombin. J Biol Chem 1994, 269:15969-15972.
13. McGee MP, Li LC, Hensler M: Functional assembly of intrinsic coagulation proteases on monocytes and platelets. Comparison between cofactor activities induced by thrombin and factor Xa. J Exp Med 1992, 176:27-35.
14. Bartha K, Brisson C, Archipoff G, de la Salle C, Lanza F, Cazenave JP, et al.: Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities in human saphenous vein endothelial cells by distinct mechanisms. J Biol Chem 1993, 268:421-429.
15. Venturini CM, Kaplan JE: Thrombin induces platelet adhesion to endothelial cells. Semin Thromb Hemost 1992, 18:275-283.
16. Shimokawa H, Flavahan NA, Vanhoutte PM: Natural course of the impairment of endothelium-dependent relaxations after balloon endothelium removal in porcine coronary arteries. Possible dysfunction of a pertussis toxin-sensitive G protein. Circulation Res 1989, 65:740-753.
17. Mosesson MW: Fibrin polymerization and its regulatory role in hemostasis. J Lab Clin Med 1990, 116:8-17.
18. Kurosawa S, Galvin JB, Esmon NL, Esmon CT: Proteolytic formation and properties of functional domains of thrombomodulin. J Biol Chem 1987, 262:2206-2212.
19. Levin EG, Stern DM, Nawroth PP, Marlar RA, Fair DS, Fenton JW II, et al.: Specificity of the thrombin-induced release of tissue plasminogen activator from cultured human endothelial cells. Thromb Haemost 1986, 56:115-119.
20. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER: Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988, 72:616-620.
21. Rapold HJ, de Bono D, Arnold AE, Arnout J, De Cock F, Collen D, et al.: Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group. Circulation 1992, 85:928-934.
22. Gram J, Munkvad S, Leebeek FW, Kluft C, Jespersen J: Reactive coagulation induced by plasmin in patients treated with recombinant tissue-type plasminogen activator. Coronary Artery Disease 1993, 4:371-377.
23. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, et al.: Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994, 90:61-68.
24. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, et al.: Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Cardiol 1995, 25:203-209.
25. Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J, Sassower M, Manzo K, et al. for the PATENT Study Group: Sequential combination thrombolytic therapy of acute myocardial infarction: results of the Pro-Urokinase and t-PA enhancement of thrombolysis (PATENT) Trial. J Am Coll Cardiol 1995, 26:374-379.
26. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM: A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1991, 324:1217-1218.
27. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL: Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infaction. Am J Cardiol 1990, 66:1412-1417.
28. de Bono DP, Simoons ML, Tijssen J, Arnold AE, Betriu A, Burgersdijk C, et al.: Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992, 67:122-128.
29. Rudd MA, George D, Amarante P, Vaughan DE, Loscalzo J: Temporal effects of thrombolytic agents on platelet function in vivo and their modulation by prostaglandins. Circ Res 1990, 67:1175-1181.
30. Friedman M, Van den Bovenkamp GJ: The pathogenesis of a coronary thrombus. Am J Pathol 1966, 48:19-44.
31. Collen D: Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus. Circulation 1991, 83:IV26-IV40.
32. Gertz SD, Kragel AH, Kalan JM, Braunwald E, Roberts WC: Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction. The TIMI Investigators. Am J Cardiol 1990, 66:904-909.
33. Fitzgerald GA: Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991, 68:11B-15B.
34. Fitzgerald DJ, Wright F, Fitzgerald GA: Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res 1989, 65:83-94.
35. Swords NA, Tracy PB, Mann KG: Intact platelet membranes, not platelet-released microvesicles, support the procoagulant activity of adherent platelets. Arterioscler Thromb 1993, 13:1613-1622.
36. Swords NA, Mann KG: The assembly of the prothrombinase complex on adherent platelets. Arterioscler Thromb 1993, 13:1602-1612.
37. Stubbs MT, Wolfram B: The clot thickens: clues provided by thrombin structure. Trens Biochem Sci 1995, 20:23-28.
38. Stubbs MT, Bode W: A model for the specificity of fibrinogen cleavage by thrombin [review]. Semin Thromb Hemost 1993, 19:344-351.
39. Young E, Prins M, Levine MN, Hirsh J: Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992 67:639-643.
40. Eitzman DT, Chi L, Schwartz RS, Lucchesi BR: Heparin neutralization by platelet-rich thrombi: Role of platelet factor 4. Circulation 1994, 89:1523-1529.
41. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990, 86:385-391.
42. Berry CN, Girardot C, Lecoffre C, Lunven C: Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thromb Haemost 1994, 72:381-386.
43. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, et al.: The structure of a complex of recombinant Hirudin and human thrombin. Science 1990, 249:277-280.
44. Rudd MA, George D, Johnstone MT, Moore RT, Collins L, Rabbani LE, et al.: Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy. Circ Res 1992, 70:829-834.
45. Markwardt F, Nowark G, Sturzebecher J, Griebach U, Walsmann P, Vogel G: Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemost 1984, 52:160-163.
46. Zoldhelyi P, Webster MW, Fuster V, Grill DE, Gaspar D, Edwards SJ, et al.: Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 1993, 88:2015-2022.
47. Lam JY, Chesebro JH, Steele PM, Heras M, Webster MW, Badimon L, et al.: Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs. Circulation 1991, 84:814-820.
48. Meyer BJ, Fernandez-Ortiz A, Mailhac A, Falk E, Badimon L, Michael AD, et al.: Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation 1994, 90:2474-2480.
49. Rubbens FD, Weitz JI, Brash JL, Kinlough-Rathbone RL: The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene. Thromb Haemost 1993, 69:130-134.
50. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, et al.: A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Col Cardiol 1994, 23:993-1003.
51. Lee LV for the TIMI 6 Investigators: Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial. Am J Cardiol 1995, 75:7-13. These two studies [50,51] are the pilot studies for hirudin in combination with thrombolytic agents.
52. The GUSTO Investigators: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The global use of strategies to open occluded coronary arteries (GUSTO) Ila investigators. Circulation 1994, 90:2147-2152.
53. Antman EM: Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994, 90:1625-1630.
54. Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinriches H, Maurer W, et al.: Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Kranenhausarzte. Circulation 1994, 90:1638-1642. These three studies [52-54] represent the initial large-scale clinical experience with hirudin and thrombolytic drugs.
55. GUSTO Gazette 1995, April-May.
56. Ofosu FA, Fenton JW, Maraganore J, Blajchman MA, Yang X, Smith L, ef al.: Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin. Biochem J 1992, 283:893-897.
57. Parry MA, Maraganore JM, Stone SR: Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry 1994, 33:14807-14814.
58. Zoldhelyi P, Bichler J, Owen WG, Grill DE, Fuster V, Mruk JS, et al.: Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994, 90:2671-2678.
59. Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Stevens P, Weitz J, et al.: Effects on thrombin generation of single injections of Hirulog in patients with calf vein thrombosis. Thromb Haemost 1994, 72:523-525.
60. Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, et al.: Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993, 69:157-163.
61. Lidon RM, Theroux P, Juneau M, Adelman B, Maraganore J: Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects. Circulation 1993, 88:1495-1501.
62. Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, et al.: Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 1993, 71:778-782.
63. Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwards P, et al.: Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994, 90:2385-2389.
64. Sharma GV, Lapsley D, Vita JA, Sharma S, Coccio E, Adelman B, et al.: Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J Cardiol 1993, 72:1357-1360.
65. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, et al.: Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993, 87:1622-1629.
66. Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R: Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995, 91:2132-2139. This study is the first experience with hirulog in patients receiving thrombolytic drugs.
67. Friedrich U, Potzsch B, Preissner KT, Muller-Berghaus G, Ehrlich H: Calcium-dependent activation of protein C by thrombin/ thrombomodulin: role of negatively charged amino acids within the activation peptide of protein C. Thromb Haemost 1994, 72:567-572.
68. Callas DD, Fareed J: Direct inhibition of protein C by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy. Thromb Res 1995, 78:457-460.
69. Bauer M, Brandstetter H, Turk D, Sturzebecher J, Bode W: Crystallographic determination of thrombin complexes with small synthetic inhibitors as a starting point for the receptor-based design of antithrombotics. Semin Thromb Hemost 1993, 19:352-360.
70. Clarke RJ, Mayo G, Fitzgerald GA, Fitzgerald DJ: Combined administration of aspirin and specific thrombin inhibitor in man. Circulation 1991, 83:1815-1817.
71. Takahashi H: Principles of the therapy for disseminated intravascular coagulation: current status and new trends. Jpn J Clin Med 1993, 51:79-86.
72. Kawada T, Mieda T, Abe H, Kamata S, Nakamura S, Endo S, et al: Left heart bypass with the bio-medicus centrifugal pump by the use of an antithrombin agent argatroban. Jpn J Thorac Surg 1994, 47:803-808.
73. Kawai H, Yamamoto T, Hara H, Tamao Y: Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban. Thromb Res 1994, 74:185-191.
74. Winn MJ, Jain K, Ku DD: Argatroban and inhibition of the vasomotor actions of thrombin. J Cardiovasc Pharmacol 1993, 22:754-760.
75. Schneider J: Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis. Thromb Res 1991, 64:677-689.
76. Valji K, Arun K, Bookstein JJ: Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis. J Vasc Intervent Radiol 1995, 6:91-95.
77. Gold HK, Torres FW, Garabedian HD, Werner W, Jang IK, Khan A, et al.: Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993, 21:1039-1047.
78. Jackson CV, Wilson HC, Growe VG, Shuman RT, Gesellchen PD: Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis. J Cardiovasc Pharmacol 1993, 21:587-594.
79. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975, 56:624-632.
80. The RAPT study group: Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 1994, 89:588-595.
81. Sharma B, Wyeth RP, Gimenez HJ, Franciosa JA: Intracoronary prostaglandin E1 plus streptokinase in acute myocardial infarction. Am J Cardiol 1986, 58:1161-1166.
82. Kleiman NS, Tracy RP, Schaaff LJ, Harris S, Hill RD, Puleo P, et al.: Prostaglandin E1 does not accelerate rTPA-induced thrombolysis in acute myocardial infarction. Am Heart J 1994, 127:738-743.
83. Topol EJ, Ellis SG, Califf RM, George BS, Stump DC, Bates ER, et al.: Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. J Am Coll Cardiol 1989, 14:877-884.
84. Kerins DM, Roy L, Kunitada S, Adedoyin A, Fitzgerald GA, Fitzgerald DJ: Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue. Circulation 1992, 85:526-532 [published erratum appears in Circulation 1992, 86:698].
85. Kerins DM, Shuh M, Kunitada S, Fitzgerald GA, Fitzgerald DJ: A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction. J Pharmacol Exp Ther 1991, 257: 487-492.
86. Nichols WW, Nicolini FA, Khan S, Saldeen TG, Mehta JL: Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs. Am Heart J 1993, 126:285-292.
87. Nichols WW, Nicolini FA, Saldeen TG, Mehta JL: Combined thrombolytic effects of tissue-plasminogen activator and a fibrinogen-degradation product peptide 6A or iloprost. J Cardiovasc Pharmacol 1991, 18:231-236.
88. Marguerie GA, Plow EF, Edgington TS: Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979, 254:5357-5363.
89. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, et al.: Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988, 77:670-677.
90. Kohmura C, Gold HK, Yasuda T, Holt R, Nedelman MA, Guerrero JL, et al.: A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler Thromb 1993, 13:1837-1842.
91. Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, et al.: Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990, 86:651-659.
92. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, et al.: Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Col Cardiol 1993, 22:381-389.
93. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994, 330:956-961.
94. Kiss RG, Stassen JM, Deckmyn H, Roskams T, Gold HK, Plow EF, et al.: Contribution of platelets and the vessel wall to the antithrombotic effects of a single bolus injection of Fab fragments of the antiplatelet GPIIb/IIIa antibody 7E3 in a canine arterial eversion graft preparation. Arterioscler Thromb 1994, 14:375-380.
95. Kiss RG, Lu HR, Roskams T, Jang IK, Plow EF, Gold HK, et al.: Time course of the effects of a single bolus injection of F(ab')2 fragments of the antiplatelet GPIIb/IIIa antibody 7E3 on arterial eversion graft occlusion, platelet aggregation, and bleeding time in dogs. Arterioscler Thromb 1994, 14:367-374.
96. Lefkovits J, Ivanhoe R, Anderson K, Weisman H, Topol EJ, for the EPIC Investigators: Platelet IIb/IIIa receptor inhibition during PTCA for acute myocardial infarction: insights from the EPIC Trial [abstract]. Circulation 1994, 90:1-564.
97. Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, et al.: Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa, J Biol Chem 1993, 268:1066-1073.
98. Scarborough RM, Rose JW, Naughton MA, Phillips DR, Nannizzi L, Arfsten A, et al.: Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem 1993, 268:1058-1065.
99. Heparin vs hirudin as adjunctive therapy for thrombolysis in MI: TIMI 9. George Washington University Symposium. Anaheim, California, November 1995.
100. Global use of strategies to open coronary arteries (GUSTO II): hirudin versus heparin in acute coronary syndromes. American College of Cardiology Symposium. Orlando, Florida, March 1996.